



This is a repository copy of *Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/154260/>

Version: Published Version

Article:

Smith, I., Swain, J., Marshall, H. et al. (4 more authors) (2015) Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment. *Trials*, 16 (S2). O79. ISSN 1745-6215

<https://doi.org/10.1186/1745-6215-16-s2-o79>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

ORAL PRESENTATION

Open Access

Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment

Isabelle Smith^{1*}, Jayne Swain¹, Helen Marshall¹, Alexandra Smith¹, Jennifer Walsh², Richard Ross², Sarah Brown¹

From 3rd International Clinical Trials Methodology Conference
Glasgow, UK. 16-17 November 2015

TRYMS is a multicentre, randomised, double-blinded, parallel group, placebo controlled phase IV trial in young male cancer survivors with low testosterone levels. The trial is designed to investigate whether testosterone treatment for 26 weeks will result in a reduction of truncal fat mass and increase in participant-reported physical functioning scores.

The general consensus worldwide is that testosterone levels ≤ 12 nmol/L are deemed to be low; however a previous study of 200 healthy volunteers found that testosterone ≤ 10 nmol/L would be deemed to be low. The trial team considered only including patients with testosterone ≤ 10 nmol/L but acknowledged this would leave an evidence gap for patients with testosterone between 10-12nmol/L. Therefore TRYMS was designed to determine whether testosterone replacement is effective in men with low testosterone and with borderline low testosterone by powering the study to look at each subgroup individually. A sample size of 268 participants was required after accounting for imbalanced recruitment to the subgroups.

However, opening TRYMS took longer than anticipated and recruitment was substantially slower than expected; the trial design was adapted to combine the subgroups for primary analysis, reducing the minimum sample size to 112 participants. The trial was granted a recruitment extension and continued to recruit beyond the minimum sample size to maximise precision of the treatment effect estimates in each subgroup; this analysis is exploratory but still considered useful to inform clinical practice. This adaptation of the trial design was a pragmatic approach for a trial struggling with recruitment, whilst still able to provide clinically useful results.

Authors' details

¹Leeds Institute of Clinical Trials Research, Leeds, UK. ²University of Sheffield, Sheffield, UK.

Published: 16 November 2015

doi:10.1186/1745-6215-16-S2-O79

Cite this article as: Smith *et al.*: Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment. *Trials* 2015 **16**(Suppl 2):O79.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Leeds Institute of Clinical Trials Research, Leeds, UK
Full list of author information is available at the end of the article